孟鲁司特联合糖皮质激素对哮喘患儿肺功能及血清IL-4和IL-25的影响

Influence of Montelukast Combined with Glucocorticoid on Lung Function,Serum IL-4 and IL-25 of Children with Asthma

目的观察白三烯受体拮抗剂孟鲁司特对6～14岁哮喘患儿肺功能和血清白细胞介素4(IL-4)、白细胞介素25(IL-25)的影响。方法将6～14岁哮喘患儿80例随机分为两组:糖皮质激素吸入干预组(A组)、在A组基础上给予白三烯受体拮抗剂孟鲁司特(B组),各40例。于治疗前和12周后检测肺功能和血清IL-4I、L-25的变化。结果两组治疗后肺功能均有所改善,以B组更加明显(P<0.05)。与治疗前比较,两组治疗后血清IL-4I、L-25均明显降低,B组降低更明显(P<0.05)。结论口服孟鲁司特联合吸入糖皮质激素能明显纠正炎性细胞因子IL-4I、L-25的异常改变,改善患儿的肺功能。

Objective To observe the influence of leukotriene receptor antagonist montelukast on lung function,interleukin-4（IL-4）and IL-25 of children between 6 to 14 years old with asthma.Methods 80 cases of children between 6 to 14 years old with asthma were randomly divided into two groups with 40 cases separately.The intervention group of inhaled corticosteroids as group A,and the group B were given the leukotriene receptor antagonist montelukast sodium based on group A.The changes of pulmonary function,the serum IL-4 and IL-25 were detected before treatment and 12 weeks after treatment.Results After treatment,the pulmonary functions of the two groups were all improved.Group B had more significant improvement than group A（P〈0.05）.Compared with the results before treatment,serum IL-4 and IL-25 of two groups after treatment decreased significantly,Group B has more significant decrease than group A（P〈0.05）.Conclusion The oral montelukast combined with inhaled corticosteroids could obviously rectify the abnormal changes of inflammatory cytokines IL-4 and IL-25 and can improve lung function of children.